|
11/16/20
|
Vaxart Hosting Key Opinion Leader Panel Call for Investors
Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics: COVID-19: Immunity & Immunological Memory Norovirus: Disease Burden & Prevention. The Current Status of Vaccine Development Mucosal Immunity and the importance of secretory IgA Administration and
|
|
11/16/20
|
Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual
|
|
11/12/20
|
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model Restarting the Norovirus program SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.
|
|
11/12/20
|
Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine
Robust Immune Response and Significantly Reduce Viral Load SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today
|
|
11/11/20
|
Vaxart Featured in USA Today Special Edition “America Recovers”
|
|
10/14/20
|
Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine
Vaccinated Hamsters Show Protection from COVID-19 based on Prespecified Indicators of Clinical Outcomes SOUTH SAN FRANCISCO, Calif. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet
|
|
10/13/20
|
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Open-label, dose ranging study to examine safety and immunogenicity First clinical data readouts in a few weeks SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by
|
|
09/14/20
|
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral vaccines that are administered by
|
|
09/08/20
|
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.
|
|
09/03/20
|
Vaxart, Inc. to Participate in September Virtual Investor Conferences
- H.C. Wainwright : 22 nd Annual Global Investment Conference - September 14 th – 16 th - Sachs Associates : 20 th Annual Biotech in Europe Forum - September 21 st – 24 th - SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th SOUTH SAN FRANCISCO, Calif. , Sept.
|
